Clinicians currently face significant challenges in peripheral T-cell lymphoma management due to the aggressive nature of these hematologic malignancies. Historically, the cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) regimen has served as the backbone of frontline therapy. However, many patients either fail to respond or experience early disease relapse. Consequently, the medical community is moving toward more personalized and targeted treatment strategies to improve long-term outcomes.

Modern Peripheral T-cell Lymphoma Management

The introduction of brentuximab vedotin (BV) represents a major milestone in treating specific subtypes. Specifically, patients with CD30-positive anaplastic large cell lymphoma (ALCL) show markedly improved progression-free survival when clinicians add BV to the frontline chemotherapy mix. Furthermore, emerging evidence supports the use of epigenetic-directed therapies and small-molecule inhibitors. These innovative approaches allow for a more tailored management plan based on the unique biological characteristics of the tumor. For example, HDAC inhibitors like belinostat have shown efficacy in the relapsed or refractory setting. Therefore, identifying biomarkers early in the diagnostic process is now a critical step for modern clinical practice.

For eligible patients, allogeneic stem cell transplantation (allo-SCT) remains the only curative option for relapsed disease. However, biological and logistical constraints often prevent the widespread application of this procedure. Moreover, researchers are actively investigating chemotherapy-free regimens and immunotherapy combinations in ongoing clinical trials. These studies aim to reduce toxicity while maintaining high response rates. Consequently, staying informed about these emerging modalities is essential for optimizing the care of this vulnerable patient population.

Frequently Asked Questions

What is the role of brentuximab vedotin in PTCL?

Brentuximab vedotin is an antibody-drug conjugate that targets CD30. It is now a standard component of frontline therapy for CD30-positive subtypes like ALCL, where it significantly improves survival outcomes compared to traditional CHOP.

When is allogeneic stem cell transplantation considered?

Allo-SCT is typically considered for younger, fit patients with relapsed or refractory disease who achieve a response to salvage therapy. It offers the best chance for a long-term cure despite its associated risks.

Are there new treatments for relapsed PTCL?

Yes, several new agents including HDAC inhibitors, pralatrexate, and PI3K inhibitors are available. Additionally, clinicians are exploring novel immunotherapies and epigenetic modifiers in clinical trials to provide more personalized care.

Disclaimer: This content is for informational and educational purposes only. It does not constitute professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified healthcare provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read here. Refer to the latest local and national guidelines for clinical practice.

References

1. Grainger BT et al. Innovative approaches for managing relapsed or refractory peripheral T-cell lymphoma. Expert Opin Pharmacother. 2026 Apr 28. doi: 10.1080/14656566.2026.2667326. PMID: 42047163.
2. National Comprehensive Cancer Network (NCCN). T-cell Lymphomas (Version 1.2025). Accessed May 2026.
3. Horwitz S, et al. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a post hoc analysis of the 5-year results. Lancet Oncol. 2022;23(2):248-258.